CP v2

Tag: University of Arizona

  • Primary progressive aphasia study tests brain stimulation to boost speech therapy and what it could mean for patients

    Primary progressive aphasia, or PPA, is a neurodegenerative condition that gradually erodes a person’s ability to communicate, often affecting speech, writing, and word retrieval. There is currently no drug proven to halt or reverse the underlying progression, so care typically focuses on supportive speech-language therapy.

    Researchers at the University of Arizona are reporting encouraging results from an approach that pairs standard speech therapy with transcranial direct current stimulation, a noninvasive method that delivers a low electrical current through electrodes placed on the scalp. The goal is to amplify therapy gains by targeting brain networks involved in language.

    How the trial was designed

    The study, published in the Journal of Speech, Language, and Hearing Research, focused on logopenic PPA, a subtype often marked by difficulty finding words and repeating phrases. The team used neuroimaging to help identify stimulation targets while avoiding brain areas that were already significantly atrophied.

    Twelve participants with written language deficits completed two treatment phases in a randomized order, separated by a two-month break. In one phase, they received speech therapy plus active stimulation, and in the other, the same therapy paired with placebo stimulation.

    What improved after stimulation

    Participants improved after both phases, but the gains were stronger and lasted longer when active stimulation was added, the researchers reported. They observed clearer writing outcomes, including fewer spelling errors and better-formed, more meaningful sentences.

    Senior author Aneta Kielar said the team’s rationale reflects how language relies not only on meaning but also on retrieving a word’s sound structure during speaking and writing. Lead researcher Katlyn Nickels noted that PPA has only been widely characterized for several decades, leaving key aspects of treatment and recovery underexplored.

    Why neuroplasticity matters in PPA

    The researchers propose that stimulation may help promote neuroplasticity, the brain’s ability to reorganize and strengthen connections that support learning. In this view, brain stimulation does not replace therapy but may boost the effects of training by making language networks more responsive.

    They also emphasized that transcranial direct current stimulation is generally described in the field as relatively inexpensive and straightforward to administer under appropriate clinical protocols. Next, the group plans to study genetic, cognitive, and neural markers that could help predict which patients benefit most and how durable improvements can be in real-world care.

    The work was supported by multiple state and university health research programs, according to the authors. While larger studies are needed to confirm results and define best practices, the findings add to growing interest in combining rehabilitation with targeted neuromodulation for neurodegenerative language disorders.

  • Precision Treatment for Depression: A New Data-Driven Model Aims to Match Patients With the Therapy Most Likely to Work

    Researchers are moving beyond trial-and-error care for depression with a precision approach designed to better match patients to treatments based on individual characteristics. The effort reflects growing evidence that depression symptoms and recovery paths vary widely from person to person.

    The project, led by psychologists at the University of Arizona and Radboud University, draws on patient-level data from randomized clinical trials across the world. Their protocol, published in PLOS One, outlines how they plan to build a clinical decision support tool for adult depression treatment selection.

    Why first-line care often fails

    Standard care frequently begins with a first-line medication or therapy and then shifts if symptoms persist, a process that can take months. The researchers point to prior findings that roughly half of patients do not respond to an initial treatment, highlighting the need for better targeting.

    Instead of offering broad guidelines, the planned tool would generate a single recommendation by weighing multiple factors at once. These include demographic information such as age and gender, along with clinical features like anxiety symptoms or personality-related difficulties.

    What data the model will use

    The team aggregated outcomes from more than 60 clinical trials involving nearly 10 000 patients, covering several widely used interventions. The treatments include antidepressant medications and multiple psychotherapy approaches, such as cognitive therapy, behavioral therapy, interpersonal therapy and short-term psychodynamic therapy.

    By combining many trials, the researchers aim to overcome limits that can affect prediction models built from single studies with smaller samples. They say the work required years of data cleaning and harmonization before analysis could begin.

    When it could reach clinics

    The next step is to develop the algorithm and then test it in a clinical trial to see whether tool-guided care improves outcomes compared with usual practice. If the results hold up, the system could be deployed as a simple software or web-based application used during routine assessments.

    The researchers argue that the inputs are intentionally practical, relying on information that can be collected through standard questionnaires and basic clinical intake. Their longer-term goal is to help clinicians and patients reach effective treatment faster while using existing mental health resources more efficiently.

  • Astrocytes move into the spotlight: New Nature study links overlooked brain cells to fear memories and PTSD pathways

    Astrocytes move into the spotlight: New Nature study links overlooked brain cells to fear memories and PTSD pathways

    Brain research is increasingly challenging the long-held idea that neurons alone drive fear and trauma responses. A new study in Nature points to astrocytes, star-shaped support cells, as active players in how fear memories are formed, recalled and reduced.

    Astrocytes are widely distributed throughout the brain and have traditionally been seen as caretakers that keep neural circuits stable. The new work suggests they can also shape signaling in the amygdala, a central hub for processing threat and generating fear-related learning.

    What the researchers observed

    Using a mouse model of fear learning, scientists tracked astrocyte activity in real time with fluorescent sensors. Astrocyte signaling rose during fear conditioning and again during memory recall, then declined as fear responses weakened through extinction training.

    The team also manipulated how astrocytes communicate with nearby neurons. Enhancing astrocyte-to-neuron signaling strengthened fear expression, while dampening those signals reduced fear responses, indicating astrocytes can tune the intensity of fear memories.

    How it changes the fear circuit

    When astrocyte activity was disrupted, neurons in the amygdala had difficulty forming the typical activity patterns associated with fear. That interference also appeared to affect how defensive-response information is routed to other brain regions involved in choosing and executing behavior.

    Researchers reported effects beyond the amygdala, including changes in fear-related signaling reaching the prefrontal cortex, an area tied to decision-making and regulation of emotional responses. The results suggest astrocytes may influence how the brain decides whether a threat response is appropriate.

    Why it matters for PTSD

    PTSD and several anxiety disorders are marked by persistent, hard-to-extinguish fear memories and heightened reactions to cues that are no longer dangerous. If astrocytes help govern both the expression and the fading of fear, they could become a complementary target alongside neuron-focused approaches.

    The researchers caution that translating mouse findings to human treatments takes time, but the study reframes fear circuitry as a partnership between neurons and glia. Next steps include mapping astrocyte roles across the wider threat network, including regions that coordinate freezing and flight responses.